Alex Ganetsky
About
Alex Ganetsky is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Alex Ganetsky has authored 35 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 15 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Ganetsky's work include Hematopoietic Stem Cell Transplantation (14 papers), Acute Lymphoblastic Leukemia research (7 papers) and Neutropenia and Cancer Infections (5 papers). Alex Ganetsky is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Acute Lymphoblastic Leukemia research (7 papers) and Neutropenia and Cancer Infections (5 papers). Alex Ganetsky collaborates with scholars based in United States, Canada and Netherlands. Alex Ganetsky's co-authors include Saar Gill, Noelle V. Frey, Alison W. Loren, Valkal Bhatt, Elizabeth O. Hexner, Mireia Uribe‐Herranz, Sònia Guedan, Andrea Facciabene, Stefano Pierini and Ceylan Tanes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Alex Ganetsky
35 papers receiving 494 citations
Peers
Alex Ganetsky
Kelty R. Baker United States
Anthony J. Perissinotti United States
Effie Liakopoulou United Kingdom
Virginia Bosó Spain
Fumihiko Monma Japan
E. Koivunen Finland
Miquel Granell Spain
Anne Nihtinen Finland
Glenda M. Davison South Africa
Michael Keng United States
Citations per year, relative to Alex Ganetsky Alex Ganetsky (= 1×)
peers
Kelty R. Baker
Countries citing papers authored by Alex Ganetsky
Since
Specialization
Citations
This map shows the geographic impact of Alex Ganetsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Ganetsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Ganetsky more than expected).
Fields of papers citing papers by Alex Ganetsky
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alex Ganetsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Ganetsky. The network helps show where Alex Ganetsky may publish in the future.
Co-authorship network of co-authors of Alex Ganetsky
This figure shows the co-authorship network connecting the top 25 collaborators of Alex Ganetsky. A scholar is included among the top collaborators of Alex Ganetsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Ganetsky. Alex Ganetsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pasin, Chloé, Alex Ganetsky, Lee P. Richman, et al.. (2021). Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. Transplantation and Cellular Therapy. 28(1). 18.e1–18.e10.
2.
Freyer, Craig W., Shannon Gier, Alex Ganetsky, et al.. (2021). Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Transplantation and Cellular Therapy. 27(5). 431.e1–431.e8.
3.
Freyer, Craig W., Alex Ganetsky, Mitchell E. Hughes, et al.. (2020). Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leukemia & lymphoma. 61(9). 2200–2207.
4.
Freyer, Craig W., Alex Ganetsky, Colleen Timlin, et al.. (2019). Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment and Length of Hospitalization in Myeloablative Allogeneic Hematopoietic Transplantation. Biology of Blood and Marrow Transplantation. 25(3). S283–S283.
5.
Reshef, Ran, Alex Ganetsky, Edward P. Acosta, et al.. (2018). Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation. 25(3). 515–521.
6.
Khera, Nandita, Betty K. Hamilton, Joseph A. Pidala, et al.. (2018). Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biology of Blood and Marrow Transplantation. 25(3). 599–605.
7.
Ganetsky, Alex, Noelle V. Frey, Elizabeth O. Hexner, et al.. (2018). Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplantation. 54(2). 212–217.
8.
Freyer, Craig W., Alex Ganetsky, Mitchell E. Hughes, et al.. (2018). Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice. Blood. 132(Supplement 1). 4023–4023.
9.
Uribe‐Herranz, Mireia, Kyle Bittinger, Stavros Rafail, et al.. (2018). Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight. 3(4).
10.
Ganetsky, Alex, et al.. (2018). Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology. 9(2). 189–200.
11.
Khera, Nandita, Betty K. Hamilton, William A. Wood, et al.. (2018). Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation. 24(3). S30–S31.
12.
Ganetsky, Alex, Jennifer Han, Mitchell E. Hughes, et al.. (2018). Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases. 68(12). 2003–2009.
13.
Kern, David M., John J. Barron, Bingcao Wu, et al.. (2017). A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. PubMed. Volume 8. 149–155.
14.
Farnia, Stephanie, et al.. (2017). Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients. Biology of Blood and Marrow Transplantation. 23(8). 1387–1392.
15.
Huffman, Austin P., Lee P. Richman, Alex Ganetsky, et al.. (2017). Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation. 24(3). 594–599.
16.
Ganetsky, Alex, Noelle V. Frey, Alison W. Loren, et al.. (2016). Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract. Blood. 128(22). 2245–2245.
17.
Barron, John, Jennifer L. Malin, Alex Ganetsky, et al.. (2016). Validity of clinical information for a novel cancer care quality program.. Journal of Clinical Oncology. 34(15_suppl). e18003–e18003.
18.
Ganetsky, Alex, Todd A. Miano, J. He, et al.. (2015). Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplantation. 51(4). 568–572.
19.
Ganetsky, Alex, Lee P. Richman, Noelle V. Frey, et al.. (2014). Vitamin D Deficiency Predicts Acute Cutaneous Graft-Versus-Host Disease in Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(2). S267–S268.
20.
Ganetsky, Alex, Mark G. Frattini, P. Maslak, et al.. (2011). Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience.. Journal of Clinical Oncology. 29(15_suppl). 6593–6593.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kelty R. Baker Breakdown of academic impact, for papers by Anthony J. Perissinotti Breakdown of academic impact, for papers by Effie Liakopoulou Breakdown of academic impact, for papers by Virginia Bosó Breakdown of academic impact, for papers by Fumihiko Monma Breakdown of academic impact, for papers by E. Koivunen Breakdown of academic impact, for papers by Miquel Granell Breakdown of academic impact, for papers by Anne Nihtinen Breakdown of academic impact, for papers by Glenda M. Davison Breakdown of academic impact, for papers by Michael Keng